- Previous Close
3.85 - Open
3.85 - Bid --
- Ask --
- Day's Range
3.85 - 3.85 - 52 Week Range
3.85 - 6.55 - Volume
1,000 - Avg. Volume
3 - Market Cap (intraday)
817.008M - Beta (5Y Monthly) -0.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.27 - Earnings Date Jun 11, 2025 - Jun 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
www.sanbio.comRecent News: SNBIF
View MorePerformance Overview: SNBIF
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNBIF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNBIF
View MoreValuation Measures
Market Cap
806.78M
Enterprise Value
789.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
40.08
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.74%
Return on Equity (ttm)
-126.57%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.88B
Diluted EPS (ttm)
-0.27
Balance Sheet and Cash Flow
Total Cash (mrq)
2.92B
Total Debt/Equity (mrq)
22.52%
Levered Free Cash Flow (ttm)
-2.17B